Centro de Documentación de Fundación MAPFRE - Why tech transfer may be critical to beating COVID-19

MAP20200026976

Why tech transfer may be critical to beating COVID-19 / Cormac O'Sullivan, Paul Rutten, Caspar Schatz. — New York : McKinsey & Company, 2020

8 p. . — (Pharmaceuticals & Medical Products Practice)

Sumario: Vaccines are considered to be our best chance for beating COVID-19, and many governments are counting on them to enable economic recovery. But to innoculate people worldwide as soon as vaccines are proven will require the pharmaceutical industry to ramp up quickly to unprecedented volumes of supply. The available global production capacity will be critical to that capability. And technology transfermoving the knowledge about and the ability to produce a vaccine from development to manufacturingwill determine how fast it happens. But tech transfer is as much a craft as a science. And it hasn't usually been on the critical path to production, so it comprises an underappreciated set of capabilities. To ensure adequate and timely supplies of COVID-19 vaccines and treatments, global institutions and pharma companies must collaborate to make tech transfer an industrialized, at-scale processbefore we need it

1. COVID-19 . 2. Coronavirus . 3. Pandemias . 4. Vacunación . 5. Desarrollo tecnológico . 6. Industria farmacéutica . 7. Innovación empresarial . 8. Laboratorios farmacéuticos . I. Rutten, Paul . II. Schatz, Caspar . III. McKinsey & Company . IV. Pharmaceuticals & Medical Products Practice . V. Título.